How we create value - Novartis Novartis in Society Integrated Report 2022
Novartis Stein Cell and Gene Therapy Facility, Switzerland
EMA CHMP recommends Novartis' cell therapy for follicular lymphoma
Learn About CAR-T Cell Therapy | NOVARTIS | HCP
Novartis commits to CAR-T manufacturing in restructure of cell therapy work | Fierce Pharma
Cell Therapy | Novartis
Novartis' Sandoz reportedly the target of $25B buyout bid from Carlyle and Blackstone | Fierce Pharma
Cell and gene data innovation and multi-stakeholder data transfer – GeneOnline Conference
Novartis' Kymriah fails to meet primary goal in non-Hodgkin lymphoma trial
Expanding CAR-T manufacturing in Europe to serve more patients | Novartis
Novartis sells Sandoz Chinese plant to Jiuzhou for $15.1M
Exforge antitrust settlement caps Novartis' year of legal disputes - Pharmaceutical Technology
Cell and Gene Therapy Manufacturing Market - Industry Analysis 2029
Novartis' Cell & Gene Therapy Storyline Deck on Behance
Novartis signs deal with BeiGene to bolster immunotherapy pipeline
Novartis Stein Cell and Gene Therapy Facility, Switzerland
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
Cell Therapy Manufacturing Improvements - BioProcess InternationalBioProcess International
Novartis' shift to superpricey cell and gene therapies draws investor ire | Fierce Pharma
Cell Therapy | Novartis
Cell-Based Therapies: 2020 & Beyond - Blue Matter Consulting
Najia GLASERMAN - Sales & Operations Planning, Supply Chain Head (ad Interim), Cell & Gene Supply Chain Management - Novartis | LinkedIn
Learn About CAR-T Cell Therapy | NOVARTIS | HCP
Novartis looks to work more strategically as a CDMO
Learn About CAR-T Cell Therapy | NOVARTIS | HCP
Cell & Gene | Novartis
